Neurocrine Biosciences Inc vs Rigetti Computing Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Rigetti Computing Inc trades at $15.44 (market cap $4.74B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.7× Rigetti Computing Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | RGTI | |
|---|---|---|
Market Cap | $17.40B | $4.74B |
Sector | Health | Technology |
52-Week High | $180.55 | $56.34 |
52-Week Low | $123.10 | $12.90 |
Enterprise Value | $16.49B | $4.33B |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →